May 07, 2019
Cesca Therapeutics to Announce Financial Results for the First Quarter Ended March 31, 2019 and Host a Conference Call on May 14
Apr 17, 2019
ThermoGenesis Releases its Enhanced X-MINI® CD3 Selection Kit for the Research Market
Apr 10, 2019
ThermoGenesis AXP® II and PXP® Systems Now Registered and Available in Thailand
Feb 25, 2019
ThermoGenesis Receives Health Canada Approval of its PXP System for Automated Processing of Bone Marrow Cells
Feb 11, 2019
ThermoGenesis Corp X-Series Control Module and Docking Stations Cleared for Labelling by TÜV Rheinland with the cTUVus Electrical Safety Mark
Feb 06, 2019
Cesca Therapeutics to Present at the BIO CEO & Investor Conference
Feb 01, 2019
ThermoGenesis Corp Signs Strategic Supply Agreement with Orthohealing Center Management to Provide it's PXP® Point-of-Care System to Orthohealing Method(TM) Physician Members
Nov 19, 2018
Cesca Therapeutics Receives 510(k) Clearance to Market Its AXP® II AutoXpress® Platform for Clinical Cord Blood Banking
Nov 14, 2018
Cesca Therapeutics Announces Third Quarter 2018 Financial Results And Provides Corporate Update
Nov 13, 2018
Cesca Therapeutics Submits Device Master File (MAF) with the FDA for the X-LAB® Automated Cell Processing Devices
Nov 07, 2018
Cesca Therapeutics To Announce Financial Results For The Third Quarter Ended September 30, 2018 And Host Conference Call On November 14
Oct 16, 2018
Cesca Therapeutics Announces Cost Reduction Measures Aimed at Achieving Cash Flow Positive Position in 2019
Sep 13, 2018
Cesca Therapeutics' Chief Executive Officer, Chris Xu, To Be The Keynote Speaker At The Cell Therapy World Asia 2018 Conference On September 20, 2018
Sep 05, 2018
Cesca Therapeutics Provides Commercialization Update For Its X-Series(TM) Product Line